KPV is a short tripeptide consisting of lysine, proline and valine that has emerged as a promising therapeutic agent for inflammatory conditions, particularly in the gut. Its mechanism of action involves interaction with cellular transporters and receptors that modulate immune responses, leading to attenuation of cytokine production, reduction of leukocyte infiltration, and restoration of mucosal barrier integrity.
The peptide transporter 1 (PepT1), encoded by the SLC15A1 gene, is a proton-coupled oligopeptide transporter expressed predominantly on the apical membrane of enterocytes in the small intestine. It facilitates the uptake of di- and tripeptides from the intestinal lumen into epithelial cells. KPV, being a tripeptide, is efficiently transported across the intestinal epithelium via PepT1. Once inside the enterocyte, KPV can interact with intracellular signaling cascades that dampen pro-inflammatory pathways.
Experimental studies in rodent models of chemically induced colitis have demonstrated that oral administration of KPV leads to significant improvements in histological scores and reductions in myeloperoxidase activity, a marker of neutrophil infiltration. These benefits are largely absent when PepT1 function is inhibited pharmacologically or genetically ablated, underscoring the transporter's essential role in delivering KPV to its site of action.
Mechanistically, intracellular KPV appears to inhibit NF-κB activation and downstream production of tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6). Additionally, it promotes the expression of tight junction proteins such as occludin and claudin-1, thereby strengthening epithelial barrier function. The net effect is a reduction in luminal antigen translocation, decreased systemic immune activation, and amelioration of intestinal inflammation.
Clinical Implications
The PepT1-mediated uptake pathway offers a strategic advantage for oral delivery of KPV, bypassing the need for invasive administration routes. Moreover, because PepT1 expression is upregulated during inflammatory states, KPV absorption may be preferentially enhanced in diseased tissue, providing a degree of targeted therapy.
Potential applications extend beyond inflammatory bowel disease to include other conditions characterized by epithelial barrier dysfunction and dysregulated immune responses, such as celiac disease and certain forms of colorectal cancer where chronic inflammation drives tumorigenesis.
Save Citation to File
To facilitate future reference, the key findings supporting KPV’s anti-inflammatory action via PepT1 can be saved in a citation manager file (e.g., .bib or .ris). The entry might include details such as author list, publication year, journal title, volume, issue, pages, DOI, and a brief abstract. Exporting this data to a shared library ensures reproducibility and easy retrieval for research collaborators.
Add to Collections
For systematic review purposes, the KPV study should be added to a dedicated collection titled "PepT1 Transporter Studies" or "Peptide-Based Anti-Inflammatory Agents." This collection can include related literature on other PepT1 substrates that modulate intestinal immunity, enabling comparative analyses and meta-analyses. Adding tags such as "tripeptide," "intestinal inflammation," "NF-κB inhibition," and "barrier integrity" will further enhance searchability within the database.
In summary, KPV’s efficacy in reducing intestinal inflammation hinges on its efficient transport by PepT1 into enterocytes, where it exerts anti-inflammatory and barrier-protective effects. The pathway offers a promising avenue for oral therapeutic strategies against gut inflammatory disorders, and systematic documentation via citation files and curated collections will support ongoing research and clinical translation.
Higit sa 30 milyong kanta na angkop sa bawat mood at okasyon
Gumawa ng sarili mong playlist
Magbahagi ng musika sa mga kaibigan at pamilya
I-save ang iyong mga paborito
Tanggalin ang iyong track
Sigurado ka bang gusto mong tanggalin ang track na ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang komento
Sigurado ka bang gusto mong tanggalin ang komentong ito?
Tanggalin ang iyong post
Sigurado ka bang gusto mong tanggalin ang post na ito?
Matagumpay na naibahagi ang kanta sa iyong timeline.
Kinakailangan ang Pagbili
Upang magpatuloy sa pakikinig sa track na ito, kailangan mong bilhin ang kanta.
Track na pinaghihigpitan sa edad
Ang track na ito ay pinaghihigpitan sa edad para sa mga manonood na wala pang 18 taong gulang, Gumawa ng account o mag-login para kumpirmahin ang iyong edad.
Gumawa ng DMCA take down notice
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Ang ulat ng komento ay matagumpay na natanggal.
Mag-ulat ng komento.
Matagumpay na natanggal ang ulat ng track.
Track ng ulat.
Matagumpay na natanggal ang ulat ng track.
Suriin ang track.
Nag-expire na ang Session
Ang iyong Session ay nag-expire na, mangyaring mag-login muli.
Isang email ng kumpirmasyon ang naipadala.
Humiling ng Refund
Magdagdag ng bagong address
Tanggalin ang iyong address
Sigurado ka bang gusto mong tanggalin ang address na ito?
Alerto sa Pagbabayad
Bibili ka na ng mga item, gusto mo bang magpatuloy?
Tanggalin ang iyong produkto
Sigurado ka bang gusto mong tanggalin ang produktong ito?
Magbayad para sa kuwento
Sigurado ka bang gusto mong magbayad para sa paggawa ng kwento?
Magbayad mula sa wallet
Bumili ng ticket
Sigurado ka bang gusto mong bumili ng ticket?
Mga Available na Ticket
Presyo
Iwanan ang kaganapan
Sigurado ka bang gusto mong umalis sa kaganapang ito?
Tanggalin ang iyong kaganapan
Sigurado ka bang gusto mong tanggalin ang kaganapang ito?
